CClinicalTrials.gg
CompletedNCT05677074Updated Apr 25, 2023

Do Patients With Fish or Shellfish Allergy Tolerate the Consumption of Fish Oil Supplements? A Clinical Study

An interventional study of Fish oil and Cod oil in Food Hypersensitivity, sponsored by University Hospital, Gentofte, Copenhagen. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-25.

Sponsored by University Hospital, Gentofte, Copenhagen · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical study is to test whether patients with fish or shellfish allergy can ingest different types of fish oil supplements without having an allergic reaction.

To achieve this, the recruited participants will be asked to:

  • provide a blood sample (used for Basophil Histamine Release Assay)
  • undergo a skin-prick-test
  • partake in multiple oral provocations

These three tests will indicate the likelihood that the participants can consume fish oil supplements without adverse allergic reactions (See the detailed description for an explanation of the tests).

The investigators will test the participants tolerance for three different types fish oil supplements: Fish oil, Cod liver oil, and krill oil.

Read the detailed description

The Basophil Histamine Release Assay is a test that indicates whether or not the immune cells of the participant reacts when it comes into contact with the fish oils.

The skin-prick-test involves the participants having their skin exposed to the fish oils. This is done by first exposing a tiny needle to the given fish oil, and then pricking the needle into the skin on the forearm of the participant. In this way, the immune cells of the skin is exposed to the fish oils. If an allergic reaction occurs, the pricked skin will swell and turn reddish.

During the oral provocation, the participant is asked to ingest small, but increasing, doses of the fish oils over a period of 2 hours. The provocation will end when either an allergic reaction occurs or the participant has ingested a total dose of 5 mL fish oil.

02

Conditions studied

  • Food Hypersensitivity
03

In context

Hypersensitivity

1,916 studies on the registry are indexed under Hypersensitivity; 265 are open to participants now.

This study's enrollment of 9 is below the median of 57 across 1,384 interventional studies indexed under Hypersensitivity.

Browse Hypersensitivity studies →

Lead sponsor

University Hospital, Gentofte, Copenhagen is the lead sponsor of 154 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult (≥18 years old)
  • Legally competent
  • Understands Danish

Exclusion criteria

Exclusion Criteria:

  • Current use of antihistamine, immunosuppressants, and/or anti-IgE-treatment that cannot be safely terminated during the study period
  • The presence of severe diseases such as: Cardiovascular disease, asthma, cancer, liver disease, kidney disease, hematological diseases, neurological diseases, dementia, immunological diseases, and endocrine diseases
  • Chronic urticaria
  • Severe atopic eczema
  • Pregnancy and/or breastfeeding
  • Participation in another clinical study the previous three months
  • Known excessive use of alcohol and/or substance abuse
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Tolerance test of fish oil, cod oil, and krill oil

    All participants will have their tolerance of three different dietary supplements tested (fish oil, cod oil, and krill oil) using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.

    Dietary Supplement: Fish oil · Dietary Supplement: Cod oil · Dietary Supplement: Krill oil

Interventions

  • Dietary supplementFish oil

    The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.

  • Dietary supplementCod oil

    The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.

  • Dietary supplementKrill oil

    The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).

06

What researchers measure

Primary outcomes

  1. Allergic reactions during fish oil provocation.

    Presence of objective allergic symptoms (i.e. hives, redness, respiratory difficulties, and changes in blood pressure) during and two hours after the oral provocation.

    Time frame: At 2 hours after the provocation or at the end of the provocation if terminated early (in case of allergic reaction).

  2. Allergic reactions during cod oil provocation.

    Presence of objective allergic symptoms (i.e. hives, redness, respiratory difficulties, and changes in blood pressure) during and two hours after the oral provocation.

    Time frame: At 2 hours after the provocation or at the end of the provocation if terminated early (in case of allergic reaction).

  3. Allergic reactions during krill oil provocation.

    Presence of objective allergic symptoms (i.e. hives, redness, respiratory difficulties, and changes in blood pressure) during and two hours after the oral provocation.

    Time frame: At 2 hours after the provocation or at the end of the provocation if terminated early (in case of allergic reaction).

Secondary outcomes

  1. Skin-prick-test

    The size of the hives are measured, if the diameter is \>3 mm it is considered a positive result, if the negative and positive control are negative and positive, respectively

    Time frame: 15 minutes after the skin-prick-test has been administered.

  2. Basophil Histamine Release Assay

    The histamine release when in contact with the fish oil is compared with the histamine release when in contact with the positive control: Phorbol 12-myristate 13-acetate (PMA) + ionomycin. A histamine release of \>10% compared to the positive control is considered a positive result.

    Time frame: At baseline

  3. Subjective allergic symptoms during oral provocations

    Subjective allergic symptoms (e.g. itchiness, throat irritation) are noted

    Time frame: At 2 hours after each provocation or at the end of the provocation if terminated early (in case of allergic reaction).

  4. Blood pressure during oral provocations

    Blood pressure (mmHg) is measured to detect possible changes from baseline,indicating the severity of an allergic reaction

    Time frame: Change in blood pressure from baseline in case of allergic reaction

  5. Pulse during oral provocations

    Pulse (beats pr. min) is measured to detect possible changes from baseline, indicating the severity of an allergic reaction

    Time frame: Change in blood pressure from baseline in case of allergic reaction

  6. Peak flow during oral provocations

    Peak flow (liters pr. minute) is measured to detect possible changes from baseline, indicating the severity of an allergic reaction

    Time frame: Change in blood pressure from baseline in case of allergic reaction

07

Study locations

1 site
  • Gentofte Hospital
    Gentofte, Hellerup 2900, Denmark
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05677074
Lead sponsor
University Hospital, Gentofte, Copenhagen
Responsible party
Lene Heise Garvey (MD, PhD, University Hospital, Gentofte, Copenhagen) — Principal investigator
First posted
Jan 10, 2023
Start date
Jan 1, 2023
Primary completion
Apr 24, 2023
Completion
Apr 24, 2023
Last update
Apr 25, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion